Evaluation of the Diagnostic Efficacy and Safety of [123I]NAV5001 as an Imaging Agent to Aid in the Diagnosis of Parkinsonian Syndromes

Summary

This is a phase 3, open-label, multiple-center, non-randomized single dose study to assess the safety and efficacy of \[123I\]NAV5001 SPECT imaging in aiding in the differentiaion of parkinsonian syndromes from non-parkinsonian tremor.

Timeline

Start

2013-11

Primary completion

2018-01

Completion

2018-01

Outcome

Outcome not reported

Stopped: “The entire drug development program for this molecule was sold to another company.”

Drugs

Indications